OncoMatch/Clinical Trials/NCT06387342
Namodenoson Treatment of Advanced Pancreatic Cancer
Is NCT06387342 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Namodenoson 25mg for pancreatic adenocarcinoma.
Treatment: Namodenoson 25mg — This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic treatment
Pancreatic adenocarcinoma has progressed on at least 1 prior systemic treatment regimen, or the patient refuses standard treatment.
Cannot have received: systemic cancer therapy
Receipt of systemic cancer therapy within 14 days prior to the Baseline Visit or concurrently during the trial.
Cannot have received: major surgery or radiation therapy
Major surgery or radiation therapy within 14 days prior to the Baseline Visit.
Cannot have received: investigational agent
Use of any investigational agent within the shorter of 4 weeks or 5 half-lives prior to the Baseline Visit.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥1.5 × 10^9/L; Platelet count ≥50 × 10^9/L
Kidney function
Creatinine clearance ≥50 mL/min (estimated glomerular filtration rate by the Cockcroft-Gault) or serum creatinine ≤2.0 mg/dL
Liver function
AST and ALT ≤10X the upper limit of normal; total bilirubin ≤10 mg/dL; serum albumin ≥2.0 g/dL
The following laboratory values must be documented prior to the first dose of study drug: Absolute neutrophil count (ANC) ≥1.5 × 10^9/L; Platelet count ≥50 × 10^9/L; Creatinine clearance ≥50 mL/min (estimated glomerular filtration rate by the Cockcroft-Gault) or serum creatinine ≤2.0 mg/dL; Aspartate aminotransferase (AST) and Alanine transaminase (ALT) ≤10X the upper limit of normal; Total bilirubin ≤10 mg/dL; Serum albumin ≥2.0 g/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06387342 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic cancer therapy, major surgery or radiation therapy, investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages